Development of De Novo Aortic Insufficiency in Patients With HeartMate 3

This study compared the development of de novo aortic insufficiency (AI), the a common adverse event after continuous-flow left ventricular assist device (LVAD) placement, between HeartMate 3 (Abbott) and HeartMate II LVAD recipients. Researchers ultimately concluded there is no significant difference in severity of AI between HeartMate II and HeartMate 3 patients.